• Cypherpunk posted net income of USD 39.4 million, swinging from a net loss of USD 16.6 million a year earlier.
• Diluted EPS was USD 0.18, versus a diluted loss per share of USD 0.40 in the prior-year quarter.
• R&D expense fell 98.13% to USD 197,000, on lower clinical and manufacturing spending following trial completion and a 2025 workforce cut.
• G&A expense climbed 147.17% to USD 4.49 million, driven by higher stock-based compensation, payroll costs, and professional fees.
• Zcash holdings rose to 323,394.38 ZEC as of Aug. 11; treasury gains reflected a USD 46 million unrealized fair-value gain in the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cypherpunk Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN24430) on August 12, 2026, and is solely responsible for the information contained therein.